Status:
COMPLETED
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
Lead Sponsor:
Emergent BioSolutions
Conditions:
T Cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to assess the safety and efficacy of treatment of non-cutaneous T-cell lymphoma with treatment with CD4.
Detailed Description
The study is closed and all subjects have completed treatment. The study is to evaluate the safety and efficacy of Humax CD4 with CHO vs CHO alone in subjects with non-cutaneous T cell lymphoma. The ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnostic biopsy of non cutaneous T Cell lymphoma with positive phenotype
- Relapsed or refractory to minimum of one course of chemotherapy
- Study is closed to enrollment.
Exclusion
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00877656
Start Date
August 1 2005
End Date
December 1 2008
Last Update
March 18 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.